16 February 2016 - Harvoni in combination with ribavirin for 12 weeks has been approved for use in chronic hepatitis C virus genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for genotype 1-infected patients with decompensated cirrhosis (Child-Pugh B or C), including those who have undergone liver transplantation.

For more details, go to: http://www.gilead.com/news/press-releases/2016/2/us-fda-approves-two-supplemental-indications-for-harvoni-in-chronic-hepatitis-c-patients-with-advanced-liver-disease